Relocation of the
European Medicines Agency

Dublin

Where the world comes to work
ARROW

Dynamic life sciences sector

A heritage steeped in science, medical innovation and regulatory excellence Ireland has a long tradition of pharmaceutical operations excellence and has been attracting and retaining foreign direct investment in the life sciences for over 50 years. Nine of the top ten global pharmaceutical companies have a presence in Ireland, with a number of these having operations in Dublin. Furthermore, over €10 billion in new investments have been made over the last 10 years in biotech manufacturing facilities in both drug substance and drug product. Key to attracting this investment has been Ireland’s strong regulatory environment and the availability of skilled life sciences professionals.



Science Foundation Ireland’s researchers collaborate with over 370 multinational companies and 437 small/medium enterprises and in 2015 increased investment in research and development from private enterprise by 44%.
Leaders in Innovation and Collaboration

Ireland also has one of the most collaborative research systems in the world. Driven by Science Foundation Ireland, there is a clear commitment to support outstanding research talent and a particular focus on the life science and ICT sectors. Innovation for future healthcare will increasingly centre on the convergence between medical device, pharmaceutical and information and communication technologies, and all three drivers come together in Dublin.

A track record of excellence in medicines regulation

Located in Dublin, the Health Products Regulatory Authority (HPRA) has an international reputation in regulatory excellence, and an exceptionally strong, established working relationship with the European Medicines Agency (EMA) and international counterparts. The agency has a demonstrated ability to evolve and adapt, now governing a unique and extensive range of health products. It is an integral part of the European network, with experts participating in and chairing or co-chairing a number of EMA committees and working groups. As a result the HPRA already provides significant support to the EMA and this can be rapidly scaled up in the event of relocation. The importance of co-operation and harmonisation is central to the HPRA's regulatory approach, as demonstrated by its commitment and involvement at the Heads of Medicines Agencies (HMA), the International Medical Device Regulators Forum (IMDRF) and the International Coalition of Medicines Regulatory Authorities (ICMRA).

Relevant links

The last decade has seen consistent and considerable public and private investment in Science, Technology and Innovation in Ireland. The result has been the establishment of a strong base of research expertise, with research excellence in a number of key strategic areas. Ireland's strategy for research and development, science and technology, Innovation 2020, aims to build on the significant successes delivered by the Government’s science strategy over the past decade, which has seen Ireland dramatically improve its performance globally in this area.